Publications - Corcept Therapeutics

PUBLICATIONS

Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.

Phase 1 Results of Exicorilant + Enzalutamide in Patients with Castration-Resistant Prostate Cancer

Linch et al • 2022 • European Society for Medical Oncology (ESMO) Congress 2022

Relacorilant + Nab-paclitaxel in Patients with Recurrent, Platinum-resistant Ovarian Cancer: Phase 2 Subgroup Analysis Mirroring the Patient Population of an Upcoming Phase 3 Study

Colombo et al • 2022 • European Society for Medical Oncology (ESMO) Congress 2022

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors

Munster et al • 2022 • Clin Cancer Res OF1–OF11

Overall survival data from a 3-arm, randomized, open-label phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer

Colombo et al • 2022 • American Society of Clinical Oncology Annual Meeting

A study of relacorilant in combination with nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)

Borazanci et al • 2022 • American Society of Clinical Oncology Annual Meeting

DAZALS: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis

Mann et al • 2022 • European Network to Cure ALS (ENCALS)

Miricorilant, a selective GR modulator, induced a rapid and significant reduction in liver fat content in a randomized, placebo-controlled phase 2a study in patients with nonalcoholic steatohepatitis

Kowdley et al • 2021 • The Liver Meeting 2021 (American Association for the Study of Liver Diseases)

Relacorilant, A Selective Glucocorticoid Receptor Modulator, In Combination With Nab-Paclitaxel Improves Progression-Free Survival In Patients With Recurrent Platinum-Resistant Ovarian Cancer: A 3-Arm, Randomized, Open-Label, Phase 2 Study

Lorusso et al. • 2021 • European Society for Medical Oncology (ESMO) Congress 2021

Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells

Greenstein et al. • 2021 • Oncotarget . 2021 Jun 22;12(13):1243-1255. doi: 10.18632/oncotarget.27989.

Adrenal tumors provide insight into the role of cortisol in NK cell activity

Greenstein et al. • 2021 • Endocr Relat Cancer . 2021 Jun 29;28(8):583-592. doi: 10.1530/ERC-21-0048.